Weight loss with atogepant during the preventive treatment of migraine: A pooled analysis
ClinicalTrials.gov identifiers: NCT02848326 (CGP-MD-01); NCT03777059 (3101-301-002); NCT03700320 (long-term safety trial); NCT03939312 (open-label extension trial); NCT03855137 (3101-303-002).
Authors
- Peter J. Goadsby (ORCID: https://orcid.org/0000-0003-3260-5904)
- Brett Dabruzzo (ORCID: https://orcid.org/0009-0008-3048-2633)
- Dale S. Bond (ORCID: https://orcid.org/0000-0002-1976-1235)
- Rosa De Abreu Ferreira
- Jessica Ailani (ORCID: https://orcid.org/0000-0001-8106-4927)
- David W. Dodick (ORCID: https://orcid.org/0000-0002-9486-6790)
- Joel M. Trugman (ORCID: https://orcid.org/0000-0002-2376-8878)
- Jonathan H. Smith (ORCID: https://orcid.org/0000-0002-0295-6773)
- Yingyi Liu (ORCID: https://orcid.org/0000-0003-2394-5106)
- B. Lee Peterlin
Institutions
- Hartford Hospital (US)
- University of California, Los Angeles (US)
- King's College London (GB)
- Georgetown University (US)
- AbbVie (United States) (US)
- Mayo Clinic Hospital (US)
- Headache Care Center (US)
- Penn State Milton S. Hershey Medical Center (US)
Publication Details
- Journal
- Cephalalgia
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1177/03331024241299753
- Citations
- 4
- Primary Topic
- Migraine and Headache Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.54
Funders
- AbbVie